The ATTRACTION-4 trial assessed the benefit of nivolumab in combination with oxaliplatin-based chemotherapy in patients with previously untreated, HER2-negative, unresectable, or recurrent gastric cancer [14]. The gene discussed is ERBB2; the disease is gastric cancer.